Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R4, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.

Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R4, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.

Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R1, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.

Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R1, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.

Abstract: Disclosed is a method of establishing working mantime in a production line comprising the steps of: numerically evaluating the work volume for the working means performed in each production process, representing the numeralized work volume as a normal work mantime, then numerically evaluating the fatigue extent of each fatigue task as a fatigue score, and adding the fatigue score to the normal work mantime.Further, the fatigue score is assigned as a fatigue recovery mantime, and the normal work mantime which includes the fatigue recovery mantime is leveled as uniform, thereby establishing a new production process which includes the leveled fatigue recovery mantime.

Abstract: A protective covering suitable for protecting the surface of an automobile against being injured owing to contact with a hard object during the assembling work or servicing in factories or maintenance shops, is disclosed which comprises a lamination of an outer thin flexible layer of engineering or semi-rigid plastic and a lining of elastic foamed plastic material, preferably shaped to conform to the contour of the body surface area to which it is applied for protection. Preferably, the covering has an engaging lug properly formed along an upper edge and at least part of a side thereof for engaging a seam or raised part of the applied area so that the covering has firm grip onto the surface, without accidentally coming off.